NEW YORK ─ DoMore Diagnostics this week announced that it has obtained the CE mark for its Histotype Px Colorectal deep-learning algorithm to predict colorectal cancer patient outcomes based on the analysis of digital histology images, enabling its clinical use in the European Union and other geographies that accept the designation.
The Oslo, Norway-based firm said the algorithm builds on research led by the Institute for Cancer Genetics and Informatics at Oslo University Hospital, and the algorithm was trained on and developed with around 100 million image tiles.
The analysis is conducted on high resolution scans from standard hematoxylin and eosin (H&E)-stained slides.
With the algorithm, clinicians and patients can receive risk information immediately after surgery, the firm said.
"The product fits well within the existing hospital workflow and adds real value to the various digital pathology platforms available," DoMore Diagnostics CEO and Cofounder Torbjørn Furuseth said in a statement.